SCHEMBL582408

SCHEMBL582408

CC(O)C(=O)OC(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
TSHR P16473 4/20 0.52
LMNA P02545 3/20 0.50
ADRB2 P07550 2/20 0.50
ADRB1 P08588 2/20 0.50
ADRB3 P13945 2/20 0.50
F2 P00734 1/20 0.50
TDP1 Q9NUW8 3/20 0.47
TP53 P04637 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
KMT2A Q03164 3/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HSD17B10 Q99714 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29117097 0.90 CA12 (0.45) ALDH1A1LMNAADRB2ADRB1ADRB3
SCHEMBL2729575 0.86 TSHR (0.54) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL28013511 0.85 TSHR (0.58) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL1162598 0.83 ALDH1A1 (0.57) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL670258 0.83 ALDH1A1 (0.57) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL582331 0.83 ALDH1A1 (0.57) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL420405 0.83 ALDH1A1 (0.57) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL13889265 0.82 TSHR (0.50) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL1532124 0.82 TSHR (0.50) ALDH1A1TSHRLMNAADRB2ADRB1
SCHEMBL31628410 0.82 LMNA (0.65) ALDH1A1TSHRLMNAADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102703331-A Methods for screening biotransformation strain of resveratrol, identifying strain and biotransforming resveratrol by using strain YONG CAO 2012-10-03 CN claimed
EP-1886677-A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders Perrine, Susan P. (US) 2008-02-13 EP claimed
EP-1611885-A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders Perrine, Susan P. (US) 2006-01-04 EP claimed
US-5939456-A METHOD OF STIMULATING THE EXPRESSION OF A GLOBIN PROTEIN, OR THE PROLIFERATION OR DEVELOPMENT OF ERYTHROID CELLS, MYELOID CELLS OR MEGAKARYOCYTIC CELLS FOR TREATING A DISORDER SELECTED FROM THE GROUP CONSISTING OF CYTOPENIA, AN ANEMIA AND NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 1999-08-17 US claimed
CN-1030608-A PREPARATION OF BACTERIAL PROTEIN BY SOLID FERMENTATION OF MIXED INOCULATED CRUDE STARCH MATERIAL AND METHOD FOR STRAIN BREEDING THEREOF GUANGDONG INST MICROBIOLOGY (CN) 1989-01-25 CN claimed
US-20230372311-A1 COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION UNIV CALIFORNIA (US) 2023-11-23 US disclosed
US-20230346788-A1 METHODS FOR TREATING VIRAL DISORDERS TRUSTEES OF BOSTON UNIVERSITY (US) 2023-11-02 US disclosed
US-11701363-B2 Methods for treating viral disorders TRUSTEES OF BOSTON UNIVERSITY (US) 2023-07-18 US disclosed
WO-2023108080-A1 BACILLUS COAGULANS STRAIN, COMPOSITIONS THEREOF, AND METHODS OF USE DEERLAND PROBIOTICS & ENZYMES, INC. (US) 2023-06-15 WO disclosed
US-20230149413-A1 HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY Viracta Subsidiary, Inc. 2023-05-18 US disclosed
US-11649377-B2 Polishing liquid, polishing liquid set and polishing method RESONAC CORPORATION (JP) 2023-05-16 US disclosed
CN-110708956-B Microcapsules comprising cycloheptanether and polyurea derived from diphenylmethane diisocyanate or an oligomer thereof in the core 巴斯夫农业公司 2022-10-04 CN disclosed
US-6197743-B1 CONCURRENT ADMINISTERING INDUCTION AGENT AND VIRICIDES THE TRUSTEES OF BOSTON UNIVERSITY 2001-03-06 US disclosed
EP-0969869-A2 COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS Perrine, Susan P. (US) 2000-01-12 EP disclosed
WO-1999040883-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FALLER DOUGLAS V (US) 1999-08-19 WO disclosed
US-5939456-A METHOD OF STIMULATING THE EXPRESSION OF A GLOBIN PROTEIN, OR THE PROLIFERATION OR DEVELOPMENT OF ERYTHROID CELLS, MYELOID CELLS OR MEGAKARYOCYTIC CELLS FOR TREATING A DISORDER SELECTED FROM THE GROUP CONSISTING OF CYTOPENIA, AN ANEMIA AND NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 1999-08-17 US disclosed
WO-1998004290-A2 COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS PERRINE SUSAN P (US) 1998-02-05 WO disclosed
CN-1030608-A PREPARATION OF BACTERIAL PROTEIN BY SOLID FERMENTATION OF MIXED INOCULATED CRUDE STARCH MATERIAL AND METHOD FOR STRAIN BREEDING THEREOF GUANGDONG INST MICROBIOLOGY (CN) 1989-01-25 CN disclosed
US-4500713-A TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AS ANTIHYPERTENSIVE AGENT USV PHARMACEUTICAL CORPORATION (US) 1985-02-19 US disclosed
US-4080209-A Photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JA) 1978-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372311-A1 COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION RBP4, ALDH1A2, RBP1 ALDH1A1 1751/4885TSHR 2820/4885LMNA 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.